Related Experiment Video

Updated: Jul 6, 2026

Measuring Cardiac Autonomic Nervous System (ANS) Activity in Toddlers - Resting and Developmental Challenges
08:22

Measuring Cardiac Autonomic Nervous System (ANS) Activity in Toddlers - Resting and Developmental Challenges

Published on: February 25, 2016

Infants and children with tachycardia: natural history and drug administration

Peter P Karpawich1, Michael D Pettersen, Pooja Gupta

  • 1Section of Pediatric Cardiology, Carmen and Ann Adams Department of Pediatrics, Children's Hospital of Medicine, Wayne State University School of Medicine, Detroit, Michigan 48230, USA. pkarpawi@dmc.org

Current Pharmaceutical Design
|April 9, 2008
PubMed

Insights

Pediatric tachyarrhythmias, often caused by developmental or genetic factors, are frequently managed with medication. This review focuses on identifying and treating these abnormal heart rhythms in infants and children.

Area of Science:

  • Pediatric Cardiology
  • Electrophysiology
  • Genetics

Background:

  • Tachyarrhythmias in the young stem from congenital heart defects, genetic ion channel abnormalities, and conduction tissue alterations, differing from adult ischemic causes.
  • Abnormal heart rhythms in children can resolve spontaneously with growth, unlike adult-onset conditions.
  • Supraventricular and ventricular tachyarrhythmias occur in the young, with atrial abnormalities being more prevalent.

Purpose of the Study:

  • To review common and uncommon fetal and infant tachyarrhythmias.
  • To emphasize electrocardiographic identification and associated congenital heart defects.
  • To detail recommended pharmacologic management strategies based on drug mechanisms.

Main Methods:

  • Review of existing literature on pediatric tachyarrhythmias.
  • Analysis of electrocardiographic findings for rhythm identification.
  • Compilation of pharmacologic treatments and dosages for infants and children.

Main Results:

  • Pharmacologic therapy is the primary intervention for infant and young child tachyarrhythmias.
  • Ablation is reserved for drug-refractory cases due to potential risks.
  • The review categorizes drug therapies by mechanism of action for specific tachyarrhythmias.

Conclusions:

  • Effective management of pediatric tachyarrhythmias relies on accurate diagnosis and tailored pharmacologic approaches.
  • Understanding the underlying causes, including genetic and developmental factors, is crucial for treatment.
  • This review provides a guide to pharmacologic agents and dosages for treating tachyarrhythmias in the young.

More Related Videos

Measuring Cardiac Autonomic Nervous System (ANS) Activity in Children09:45

Measuring Cardiac Autonomic Nervous System (ANS) Activity in Children

Published on: April 29, 2013

Related Concept Videos

Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...